Gynecology & Obstetrics Case report Open Access

  • ISSN: 2471-8165
  • Journal h-index: 7
  • Journal CiteScore: 0.44
  • Journal Impact Factor: 1.86
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days

Short Communication - (2024) Volume 10, Issue 2

Gynecologic Tumor Surgery Advances: The Development and Results of Robotic Surgery for Gynecologic Cancers in a Tertiary Center
David Yoav
1Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada, Canada

Received: 02-Mar-2024, Manuscript No. ipgocr-24-19970; Editor assigned: 04-Mar-2024, Pre QC No. P-19970; Reviewed: 16-Mar-2024, QC No. Q-19970; Revised: 22-Mar-2024, Manuscript No. R-19970; Published: 29-Mar-2024, DOI: 10.36648/2471-8165.10.02.19


Surgical intervention remains a cornerstone in the treatment of gynecologic cancers, which include malignancies of the ovaries, cervix, uterus, vulva, and vagina. Over the past two decades, there have been significant advancements in surgical techniques, particularly with the advent of minimally invasive surgery (MIS). Among the innovations in MIS, robotic-assisted surgery has emerged as a transformative approach, offering numerous benefits over traditional open and even conventional laparoscopic surgeries. This article explores the development and outcomes of robotic surgery for gynecologic cancers at a tertiary center, highlighting the technological advancements, clinical results, and future directions in this field [1].


Robotic surgery was introduced in the late 1990s and early 2000s, with the da Vinci Surgical System becoming the first FDA-approved robotic platform for general laparoscopic surgery in 2000. The application of robotic technology in gynecology began shortly thereafter, with the first robotic-assisted hysterectomy performed in 2005. Since then, the technology has been rapidly adopted in gynecologic oncology for complex procedures such as radical hysterectomy, pelvic and para-aortic lymphadenectomy, and ovarian cancer debulking. The robotic arms offer a greater range of motion than human hands, allowing for precise dissection and suturing in confined spaces. The high-definition, magnified 3D vision system provides superior visualization of the surgical field, enhancing the surgeon’s ability to identify and preserve critical structures. The console setup allows surgeons to operate in a seated position, reducing physical strain and fatigue during lengthy procedures. These technological advantages have contributed to the growing adoption of robotic surgery in gynecologic oncology. The implementation of a robotic surgery program at a tertiary center involves several critical steps: Acquiring the da Vinci Surgical System or other robotic platforms requires significant financial investment. Hospitals must evaluate the cost-effectiveness based on projected surgical volumes and potential benefits. Surgeons undergo specialized training in robotic techniques, often starting with simulation and progressing to proctored cases. Proficiency in conventional laparoscopy is a prerequisite for robotic training [2,3]. Successful implementation requires a coordinated effort from a multidisciplinary team, including anesthesiologists, surgical assistants, nursing staff, and perioperative personnel. Initial cases typically involve patients with less complex pathology to build experience and optimize outcomes. The introduction of robotic surgery for gynecologic cancers at our tertiary center has yielded promising results. While initial cases may involve longer operative times, these decrease significantly with experience. Studies have shown that the learning curve for robotic hysterectomy averages around 20-30 cases. Robotic surgery is associated with reduced intraoperative blood loss and lower transfusion rates compared to open surgery. This is attributed to the precision and hemostatic capabilities of the robotic system. Patients undergoing robotic surgery typically experience shorter hospital stays and faster recovery times. Minimally invasive approaches reduce postoperative pain, allowing for earlier mobilization and return to normal activities. Oncologic outcomes, including surgical margins and lymph node yield, are comparable to those achieved with open surgery. Robotic surgery facilitates thorough lymphadenectomy and meticulous dissection, crucial for staging and cytoreductive procedures [4,5].


Future advancements in robotic surgery aim to enhance the capabilities and reduce the limitations of current systems. Innovations such as haptic feedback, improved instrument articulation, and integration with augmented reality for enhanced navigation are on the horizon. These technologies will further improve the precision and safety of robotic surgery. Ensuring that surgeons and surgical teams maintain proficiency in robotic techniques is crucial. Ongoing education and simulation-based training are essential components of a successful robotic surgery program. Additionally, standardized credentialing processes and outcome monitoring can help maintain high standards of care. Continued research is needed to further evaluate the long-term outcomes and benefits of robotic surgery in gynecologic oncology. Comparative studies and randomized controlled trials can provide robust evidence to guide clinical practice and policy decisions. Additionally, investigating patient-reported outcomes and quality of life measures will help assess the holistic impact of robotic surgery. The development and implementation of robotic surgery for gynecologic cancers at a tertiary center have marked a significant advancement in the field. The technological innovations of robotic systems provide numerous benefits, including enhanced precision, reduced blood loss, shorter hospital stays, and faster recovery times. While challenges such as cost and accessibility remain, ongoing research and technological advancements promise to further improve the outcomes and expand the applications of robotic surgery in gynecologic oncology. By embracing these advancements, healthcare providers can offer patients more effective and less invasive surgical options, ultimately enhancing the quality of care for women with gynecologic malignancies.



Conflict of Interest

The author has no conflicts of interest to declare.


  1. Martincorena I, Campbell PJ (2015) Somatic mutation in cancer and normal cells. Sci 349(6255): 1483-1489.
  2. [Google Scholar], [Crossref], [Indexed at]

  3. Frank SA, Nowak MA (2004) Problems of somatic mutation and cancer. Bioessays 26(3): 291-299.
  4. [Google Scholar], [Crossref], [Indexed at]

  5. Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, et al. (2016) Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nat 534(7605): 47-54.
  6. [Google Scholar], [Crossref], [Indexed at]

  7. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, et al. (2007) Patterns of somatic mutation in human cancer genomes. Nat 446(7132): 153-158.
  8. [Google Scholar], [Crossref], [Indexed at]

  9. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, et al. (2015) COSMIC: Exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 43(D1): D805-D811.
  10. [Google Scholar], [Crossref], [Indexed at]

Citation: Yoav D (2024) Colposcopy: A Comprehensive Guide. Gynecol Obstet Case Rep. Vol.10 No.2:19.

Copyright: © Yoav D. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.